From “good news” to “failure”: how French participants experienced an HIV remission trial
'We finally understand what we have to do': antibody studies point the way to an HIV cure
Lean people with HIV can still develop fatty liver disease
Returning to HIV care does not erase the effects of treatment interruption, studies show
Alternative first-line HIV regimen limits excess weight gain
Once-weekly islatravir / lenacapavir combination pill maintains HIV viral suppression
Islatravir plus ulonivirine shows promise for weekly oral HIV treatment
Dolutegravir knocks down HIV faster than bictegravir
Long-acting injectable treatment superior to daily pills for adolescents in African trial
